Carlos Fonte, MD
Cardiovascular Disease · Las Vegas, NVNPI 1215979604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,778 of the $7,782 with a category attached, or 87.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,828 and has fallen 74.5% since, to $466 in 2025.
Across 371 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- Novartis$880
- AstraZeneca$543
- Sanofi-aventis U.S. LLC$410
- Boehringer Ingelheim$406
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,77887%
- Education$1,00413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $1,599 |
| Johnson & Johnson | 80 | $1,190 |
| Novartis | 53 | $880 |
| AstraZeneca | 9 | $543 |
| Sanofi-aventis U.S. LLC | 22 | $410 |
| Boehringer Ingelheim | 22 | $406 |
| E.r. Squibb & Sons, L.L.C. | 19 | $367 |
| Merck | 15 | $272 |
| Nevro Corp. | 3 | $240 |
| Amarin Pharma, Inc. | 14 | $224 |
| Medtronic(2 entities) | 6 | $223 |
| Impulse Dynamics (USA) Inc. | 3 | $174 |
| Bayer | 8 | $141 |
| Esperion Therapeutics, Inc. | 8 | $139 |
| Abbott | 6 | $112 |
| Pfizer | 7 | $107 |
| Astellas Pharma US Inc | 6 | $99 |
| Novo Nordisk | 5 | $96 |
| Alnylam Pharmaceuticals Inc. | 3 | $89 |
| Boston Scientific | 5 | $83 |
| Bard Peripheral Vascular, Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Irhythm Technologies, Inc. | 3 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Edwards Lifesciences | 1 | $32 |
| Lundbeck LLC | 1 | $25 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Koya Medical, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$785
- FARXIGA$246
- Reveal LINQ$147
- Senza Spinal Cord Stimulation System$117
- OPTIMIZER$113
How this compares
$7,782 in reported general payments places this provider in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 376 | $356,311 |
| XareltoRivaroxaban | 315 | $320,277 |
| EntrestoSacubitril/Valsartan | 80 | $85,488 |
| FarxigaDapagliflozin Propanediol | 36 | $31,742 |
| Repatha SureclickEvolocumab | 36 | $21,492 |
| Praluent PenAlirocumab | 15 | $7,043 |
| Metoprolol Succinate | 492 | $6,086 |
| Flecainide Acetate | 98 | $5,512 |
| Rosuvastatin Calcium | 432 | $4,797 |
| Nebivolol Hcl | 71 | $4,411 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 160 | $3,866 |
| Losartan Potassium | 447 | $3,801 |
| Spironolactone | 407 | $3,623 |
| VascepaIcosapent Ethyl | 11 | $3,609 |
| Amlodipine Besylate | 616 | $3,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $107 | $356,311376 claims |
| Johnson & JohnsonXarelto | $1,190 | $320,277315 claims |
| NovartisEntresto | $880 | $85,48880 claims |
| AstraZenecaFarxiga | $543 | $31,74236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.